<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00207064</url>
  </required_header>
  <id_info>
    <org_study_id>363055</org_study_id>
    <secondary_id>H-KF-01-078/97</secondary_id>
    <nct_id>NCT00207064</nct_id>
  </id_info>
  <brief_title>Neurobiological and Neurocognitive Disturbances in First-episode Schizophrenia</brief_title>
  <official_title>5-HT2A-receptor Binding: Implications for the Pathophysiology of Schizophrenia and Effects of Treatment With Antipsychotic Drugs</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Birte Glenthoj</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Copenhagen University Hospital, Hvidovre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Glostrup University Hospital, Copenhagen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Danish Medical Research Council</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Copenhagen Hospital Corporation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Copenhagen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Copenhagen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We want to relate disturbances in first-episode schizophrenic patients in serotonin 5-HT2A
      receptors, brain structure, brain function, and information processing to each other and to
      psychopathology. Additionally, we want to examine the influence of 5-HT2A receptor blockade
      on these disturbances. We expect disturbances in the serotonergic system at baseline to
      correlate with specific structural and functional changes and with disruption in information
      processing as measured with psychophysiological and neurocognitive methods - and we expect
      5-HT2A receptor blockade to reverse some of the functional and cognitive impairments. We do
      not expect any effect of treatment on brain structure
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients and matched healthy controls are examined at baseline and again after the patients
      have been treated for 6 months with a combined 5-HT2A- and dopamine D2- receptor blocker. We
      have chosen the atypical antipsychotic compound, quetiapine, for the present study since this
      drug is characterized by a fast koff/low affinity for the dopamine D2 receptors. The purpose
      of the study is to examine pathophysiological and neuropsychological mechanisms - not
      treatment effects. We want to characterize neurobiological and functional endophenotypes or
      vulnerability indicators and to study their stability over time and their relation to
      treatment and contemporary psychopathology. To the extent that candidate endophenotypes can
      be characterized as stable and independent of treatment and contemporary psychopathology they
      will be analysed together with similar findings from previous (identical)cohorts of
      schizophrenic patients. Specific disturbances will also be related to candidate genes for
      schizophrenia.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2004</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <primary_completion_date type="Actual">September 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>5-HT2A receptor binding and occupancy (PET)</measure>
    <time_frame>Baseline and after 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Structural MRI</measure>
    <time_frame>Baseline and after 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Functional MRI</measure>
    <time_frame>Baseline and after 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Information procession as measured with psychophysiological methods (P300, PPI, P50 gating ect.)</measure>
    <time_frame>Baseline and after 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>An extensive battery of neurocognitive measures</measure>
    <time_frame>Baseline and after 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>PANSS</measure>
    <time_frame>Baseline and after 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>quetiapine</intervention_name>
    <description>flexible doses according to the clinical condition</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  First-episode schizophrenia. The controls are matched for age, gender and parental
             socioeconomic status

        Exclusion Criteria:

          -  Previous antipsychotic treatment, mental retardation, organic brain damage, and for
             the controls a psychiatric diagnosis or first-degree relatives with a psychiatric
             diagnosis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Birte Glenthoj, MD, DMSc.</last_name>
    <role>Study Director</role>
    <affiliation>Center for Neuropsychiatric Schizophrenia Research, University of Copenhagen, Psychaitric Center Glostrup, Ndr. Ringvej, DK-2600 Glostrup, Denmark</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Neurobiology Research Unit, Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>DK-2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Neuropsychiatric Schizophrenia Research, University of Copenhagen, Psychiatric Center Glostrup</name>
      <address>
        <city>Glostrup</city>
        <zip>DK-2600</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Danish Research Center for Magnetic Resonance Imaging, Hvidovre Hospital</name>
      <address>
        <city>Hvidovre</city>
        <zip>DK-2650</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <link>
    <url>http://www.cnsr.dk</url>
    <description>Center for Neuropsychiatric Schizophrenia Research (CNSR)</description>
  </link>
  <verification_date>September 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 10, 2005</study_first_submitted>
  <study_first_submitted_qc>September 20, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2005</study_first_posted>
  <last_update_submitted>September 16, 2011</last_update_submitted>
  <last_update_submitted_qc>September 16, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 19, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Copenhagen</investigator_affiliation>
    <investigator_full_name>Birte Glenthoj</investigator_full_name>
    <investigator_title>Professor of Psychopharmacology and Neuropsychiatry, Danish Center for Neuropsychiatric Schizophrenia Research</investigator_title>
  </responsible_party>
  <keyword>first-episode</keyword>
  <keyword>altanserin</keyword>
  <keyword>5-HT2A receptors</keyword>
  <keyword>MRI</keyword>
  <keyword>fMRI</keyword>
  <keyword>PPI</keyword>
  <keyword>P300</keyword>
  <keyword>P50 gating</keyword>
  <keyword>endophenotypes</keyword>
  <keyword>vulnerability indicators</keyword>
  <keyword>quetiapine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Quetiapine Fumarate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

